KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) Income from Continuing Operations (2017 - 2026)

Moderna (MRNA) has disclosed Income from Continuing Operations for 10 consecutive years, with 1343000000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 38.31% year-over-year to 1343000000.0; the TTM value through Mar 2026 reached 3194000000.0, up 4.86%, while the annual FY2025 figure was 2822000000.0, 20.75% up from the prior year.
  • Income from Continuing Operations hit 1343000000.0 in Q1 2026 for Moderna, down from 826000000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 3657000000.0 in Q1 2022 and bottomed at 3630000000.0 in Q3 2023.
  • Average Income from Continuing Operations over 5 years is 239882352.94, with a median of 825000000.0 recorded in 2025.
  • Year-over-year, Income from Continuing Operations surged 199.51% in 2022 and then plummeted 1638.46% in 2025.
  • Moderna's Income from Continuing Operations stood at 1465000000.0 in 2022, then tumbled by 85.19% to 217000000.0 in 2023, then tumbled by 616.13% to 1120000000.0 in 2024, then grew by 26.25% to 826000000.0 in 2025, then plummeted by 62.59% to 1343000000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 1343000000.0, 826000000.0, and 200000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.